Nureca Intrinsic Value
Nureca (NURECA) median intrinsic value is ₹288.00 from 3 valuation models (range ₹93–₹388), vs current price ₹229.04 — +25.7% upside (Trading Below Calculated Value), margin of safety 20.5%. Read NURECA dividend growth for the complete payout history and dividend yield track record.
NURECA Valuation Methods Summary — DCF, Graham Number & P/E
Nureca intrinsic value across 3 models vs current price ₹229.04 — upside/downside and value range per method. Analyse NURECA shareholding pattern to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹388.00 | ₹349.20 - ₹426.80 | +69.4% | Book Value/Share: ₹194.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹288.00 | ₹259.20 - ₹316.80 | +25.7% | Revenue/Share: ₹144.00, P/S: 2.0x |
| Simple DCF (5Y) | dcf | ₹92.84 | ₹74.27 - ₹111.41 | -59.5% | CF Growth: 5.0%, Discount: 15% |
NURECA Intrinsic Value vs Market Price — All Valuation Models
Nureca fair value range ₹93–₹388 vs current market price ₹229.04 across 3 valuation models. For current market price and key ratios, visit Nureca share price screener.
NURECA Intrinsic Value Analysis — Undervalued or Overvalued?
Nureca median intrinsic value ₹288.00, current price ₹229.04 — Trading Below Calculated Value by 25.7%, margin of safety 20.5%.
What is the intrinsic value of NURECA?
Based on our comprehensive analysis using 3 different valuation methods, the estimated intrinsic value of Nureca (NURECA) is ₹288.00 (median value). With the current market price of ₹229.04, this represents a +25.7% variance from our estimated fair value.
The valuation range spans from ₹92.84 to ₹388.00, indicating ₹92.84 - ₹388.00.
Is NURECA undervalued or overvalued?
Based on our multi-method analysis, Nureca (NURECA) appears to be trading below calculated value by approximately 25.7%.
NURECA Financial Health — Key Ratios vs Industry Benchmarks
Nureca financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 63.33 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -12.4% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -16.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.69x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
NURECA Cash Flow Quality — Operating & Free Cash Flow
Nureca operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-19 Cr | ₹-19 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹10 Cr | ₹2 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹1 Cr | ₹-1 Cr | Positive Operating Cash Flow | 6/10 |
| March 2021 | ₹35 Cr | ₹-20 Cr | Positive Operating Cash Flow | 6/10 |